Current tools utilised in clinical practice to predict response to anti-PD-(L)1 therapy include assessments of PD-L1 expression on tumour tissue and within the TME, and tumour mutational burden (TMB) [45,46]. This evidence concerns the gene CD274 and neoplasm.